Quick Answer
NOVAVAX INC reported Total Revenue of $1.12 billion for fiscal year 2025.
NOVAVAX INC Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $1.12B | +64.7% |
| 2024 | $682.16M | -30.7% |
| 2023 | $983.71M | -50.4% |
| 2022 | $1.98B | +72.9% |
| 2021 | $1.15B | +141.0% |
| 2020 | $475.60M | +2448.5% |
| 2019 | $18.66M | -45.6% |
| 2018 | $34.29M | +10.0% |
| 2017 | $31.18M | +103.1% |
| 2016 | $15.35M | -57.6% |
| 2015 | $36.25M | +18.2% |
| 2014 | $30.66M | +46.6% |
| 2013 | $20.91M | -5.3% |
| 2012 | $22.08M | +50.3% |
| 2011 | $14.69M | +4182.2% |
| 2010 | $343.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.44M | -16.6% | -70.6% |
| June 30, 2025 | $239.24M | -42.4% | -64.1% |
| March 31, 2025 | $666.65M | +610.3% | +688.8% |
| September 30, 2024 | $84.51M | -54.8% | -79.7% |
| June 30, 2024 | $415.48M | -2.1% | +342.7% |
| March 31, 2024 | $93.86M | +15.9% | -49.8% |
| September 30, 2023 | $186.99M | -74.5% | -55.9% |
| June 30, 2023 | $424.43M | +128.3% | +424.3% |
- NOVAVAX INC showed an increase of +64.7% in Total Revenue compared to the prior fiscal year.
- Over the 2010–2025 period, NOVAVAX INC’s total revenue has grown by 327444.9% (from $343.0 thousand to $1.12 billion).
- The most recent figure is from NOVAVAX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: